EDISON, N.J., Oct. 13 /PRNewswire-FirstCall/ -- Intelligroup Inc., a global provider of strategic consulting services and partner to some of the world's largest companies today announced the completion of Oracle(R) E- Business Suite implementation for Telik, a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer. Intelligroup's demonstrated domain knowledge and Life Sciences expertise were essential to delivering a fully functional and compliant ERP system in just five months.
Using Oracle's application implementation methodology to guide the process, the Intelligroup team, a Partner in the Oracle PartnerNetwork, implemented Oracle Financials, Oracle Internal Controls Manager, and Oracle Supply Chain. Additionally, using industry best practices with adherence to Telik's Corporate Quality Assurance standards and GMP/FDA guidelines, Intelligroup validated the implementation to ensure regulatory compliance.
"Meeting our timeline for implementation and validation was critical to Telik attaining its strategic business objectives," said Wendy Wee, VP and Controller of Telik. "Intelligroup's knowledge of both Oracle and the compliance/validation issues helped Telik meet its timeline and provided the quality consulting services promised."
"Intelligroup is very pleased to add Telik to our long list of satisfied customers," said Sivakumar Rajagopalan, Vice President of Intelligroup's Life Science Practice. "It is always gratifying to work with clients to improve efficiencies and provide services that enable business process improvements to meet organizational objectives."
"Intelligroup's proven Global Delivery Model, extensive vertical knowledge, and expertise in Oracle Process Manufacturing and Oracle Financials were instrumental in bringing this project to a successful conclusion -- on time and within budget," said Srinivas BK, Intelligroup's Associate Director, Oracle Practice.
About Oracle PartnerNetwork
Oracle PartnerNetwork is a global business network of 15,000 companies who deliver innovative enterprise software solutions based on Oracle software. Through access to Oracle's premier products, education, technical services, marketing and sales support, the Oracle PartnerNetwork program provides partners with the resources they need to be successful in today's global economy. Oracle partners are able to offer customers' leading-edge solutions backed by Oracle's position as the world's largest enterprise software company. http://oraclepartnernetwork.oracle.com
About Telik
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat cancer. The company's most advanced drug development candidate is TELCYTA(TM) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non- small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com
About Intelligroup
Intelligroup is a strategic partner to the world's largest companies. Its proven onsite/offshore delivery model has enabled hundreds of customers to accelerate results and reduce costs up to 50%. With deep expertise in industry-specific enterprise solutions, Intelligroup has earned a reputation for consistently exceeding client expectations. Intelligroup develops, implements and supports IT solutions for some of the largest U.S. school systems and global corporations including GE, Hershey, Abbott Labs, Eastman Chemical, Hitachi, and Kimball International.
Safe Harbor Statement
Certain statements contained herein, including statements regarding the development of services and markets and future demand for services and other statements regarding matters that are not historical facts, are forward- looking statements (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include risks and uncertainties; consequently, actual results may differ materially from those expressed or implied thereby. Certain of such risks and uncertainties are set forth in Intelligroup's filings with the Securities and Exchange Commission.
Trademarks
Oracle, JD Edwards, and PeopleSoft are registered trademarks of Oracle Corporation and/or its affiliates.
Intelligroup Inc.CONTACT: Investor Relations - investor.relations@intelligroup.com,+1-732-362-2380, For all other topics, marketing@intelligroup.com,+1-732-362-2206
